Metastasis-Directed Therapy Shows Promise in Oligorecurrent Prostate Cancer
For patients with oligorecurrent prostate cancer, androgen deprivation therapy–free survival was superior for those assigned to metastasis-directed therapy versus surveillance.
Source: OncLive